Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Metastatic breast cancer (MBC) is generally incurable. However, 10–20-year relapse-free survival of MBC is approximately 2%, implying that at least a small subset of MBC patients achieve prolonged survival. We therefore analyzed long-term outcome in a particular subset, i.e., oligometastatic breast cancer (OMBC).
Data of OMBC subjects (N = 75) treated in our institution from April 1980 to March 2010 were retrospectively analyzed. OMBC was identified as: one or 2 organs involved with metastatic lesions (excluding the primary lesion resectable by surgery), fewer than 5 lesions per metastasized organ, and lesion diameter less than 5 cm. Patients were generally treated with systemic chemotherapy first, and those who achieved complete response (CR) or partial response (PR) were further treated, if applicable, with local therapy (surgical or radiation therapy) to maintain CR or to induce no evidence of clinical disease (NED), with additional systemic therapy.
Median follow-up duration was 103 (6–329) months. Single or 2 organs were involved in, respectively, 44 (59%) and 31 (41%) cases with metastatic lesions, 48% of which were visceral. In cases where effects of systemic therapy, possibly in combination with other treatments, were evaluated (N = 68), CR or PR was achieved in 33 (48.5%) or 32 (47.1%), respectively, with overall response rate (ORR: CR + PR) of 95.6% (N = 65). In cases receiving multidisciplinary treatment (N = 75), CR or NED (CR/NED), or PR was induced in 48 (64.0%) or 23 (30.7%) cases, respectively, with ORR (CR/NED + PR) of 94.7% (N = 71). CR rates (60.5%) with systemic therapy and CR/NED rates (79.5%) with multidisciplinary treatment were significantly better in subjects with a single involved organ than in those with two involved organs (P = 0.047 and 0.002, systemic only or multidisciplinary treatments, respectively).
Medians estimated by Kaplan–Meier method were: overall survival (OS) of 185.0 months and relapse-free interval (RFI) of 48.0 months. Estimated outcomes were: OS rates (OSR) of 59.2% at 10 years and 34.1% at 20 years, and relapse-free rates (RFR) of 27.4% at 10 years and 20 years. No disease progression was observed after 101.0 months as RFR. Cases with single organ involvement (N = 44) showed significantly better outcomes (OSR of 73% at 10 years and 52% at 20 years, RFR of 42% at 10 years and 20 years). Those who received local therapies (N = 35) also showed better prognosis: OSR of 82% at 10 years and 53% at 20 years, RFR of 38% at 10 years and 20 years. Three cases (4%) survived for their lifetime without relapse after achieving CR or NED, our definition of clinical cure.
Multivariate analysis revealed factors favoring better prognosis as: none for OS, and single organ involvement with metastasis, administration of local treatment, and shorter disease-free interval (DFI) (P = 0.030, 0.039, and 0.042, respectively) for RFR. Outcomes in OMBC in literature were OSR of 35–73% at 10 years and 26–52% at 20 years, and RFR of 27–42% at 10 years and 26–42% at 20 years.
The present analyses clearly indicate that OMBC is a distinct subgroup with long-term prognosis superior to MBC, with reasonable provability for clinical cure. Further prospective studies to better characterize OMBC are warranted to improve prognosis in MBC.
- Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review
Volume 19, Issue 3 , pp 218-237
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Oligometastatic breast cancer
- Metastatic breast cancer
- Relapse-free survival
- Clinical cure
- Industry Sectors
- Tadashi Kobayashi (1)
- Tamotsu Ichiba (1)
- Toshikazu Sakuyama (1)
- Yasuhiro Arakawa (1)
- Eijiroh Nagasaki (1)
- Keisuke Aiba (1)
- Hiroko Nogi (2)
- Kazumi Kawase (2)
- Hiroshi Takeyama (2)
- Yasuo Toriumi (2)
- Ken Uchida (2)
- Masao Kobayashi (3)
- Chihiro Kanehira (3)
- Masafumi Suzuki (4)
- Naomi Ando (5)
- Kazuhiko Natori (6)
- Yasunobu Kuraishi (6)
- Author Affiliations
- 1. Department of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan
- 2. Department of Breast and Endocrine Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan
- 3. Department of Therapeutic Radiology, The Jikei University School of Medicine, 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan
- 4. Department of Pathology, The Jikei University School of Medicine, 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan
- 5. Department of Pharmacology, The Jikei University Hospital, 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan
- 6. Department of Hematology and Oncology, Toho University Omori Medical Center, 6-11-1, Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan